Clinical Trials on Inflammatory Bowel Diseases in Germany

Total 21707 results

Pfizer
Arena is a wholly owned subsidiary of Pfizer

Recruiting

A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease (CULTIVATE)

Crohn's Disease

United States, Korea, Republic of, Netherlands, Colombia, Israel, Italy, Lebanon, Mexico, Poland, Spain, Turkey, Australia, Georgia, Czechia, Belgium, Germany, South Africa, Greece, Russian Federation, United Kingdom, Croatia, Serbia and more
AbbVie

Active, not recruiting

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433

Crohn's Disease

United States, Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy and more
Pfizer

Not yet recruiting

A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis (EFFECT-UC)

Colitis, Ulcerative

United Kingdom, Germany
Eli Lilly and Company

Completed

A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (VIVID-1)

Crohn's Disease

China, United States, Spain, Australia, Austria, Belgium, India, Japan, Korea, Republic of, Israel, Russian Federation, Canada, Hungary, Poland, Italy, Turkey, Switzerland, Germany, Brazil, Argentina, Latvia, Romania, Slovakia, Ukraine, Denmar... and more
UCB Pharma SA

Completed

A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease (PRECiSE 4)

Crohn's Disease

United States, Australia, Austria, Belarus, Belgium, Bulgaria, Canada, Czechia, Denmark, Estonia, Germany, Hungary, Israel, Italy, New Zealand, Norway, Poland, Russian Federation, Serbia, Singapore, Slovenia, South Africa, Spain, Ukraine
AbbVie

Active, not recruiting

A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease

Crohn's Disease (CD)

United States, Belgium, Canada, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Netherlands, New Zealand, Norway, Poland, Romania, Slovakia, Spain, United Kingdom
AstraZeneca
MedImmune Ltd

Completed

Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.

Crohn's Disease

United States, France, Italy, Poland, Germany, Spain, Canada, Hungary, Czechia
AbbVie

Completed

A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

Crohn's Disease | Ulcerative Colitis (UC)

United States, Germany, Israel
UCB Pharma SA

Completed

A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] (PRECiSE 3)

Crohn's Disease

United States, Australia, Austria, Belarus, Belgium, Bulgaria, Czechia, Denmark, Estonia, Germany, Hungary, Israel, Italy, New Zealand, Norway, Poland, Russian Federation, Serbia, Singapore, Slovenia, South Africa, Spain, Ukraine, Canada and more
AstraZeneca

Terminated

Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants With Active, Moderate to Severe Crohn's Disease

Crohn's Disease

United States, France, Italy, Belgium, Australia, Canada, Hungary, Russian Federation, Spain, Germany, Netherlands, Israel
Charite University, Berlin, Germany

Unknown

Perfusion Rate Assessment by Near-infrared Fluorescence in Gastrointestinal Anastomoses

Pancreatic Neoplasms | Crohn Disease | Ulcerative Colitis | Familial Adenomatous Polyposis | Diverticulitis | Hepatobiliary Neoplasm | Bowel Obstruction | Cancer of the Gastrointestinal Tract | Stoma Ileostomy | Bowel Ischemia | Abnormality of the Gastrointestinal Tract | Symptomatic Disorders of the Gastrointestinal...

Germany
UCB Pharma

Completed

Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease

Crohn Disease

United States, Australia, Italy, Ukraine, Germany, Belgium, Israel, Romania, Canada, New Zealand, Brazil, Estonia, Russian Federation, Chile, Austria, Poland, Hungary, Latvia, Czechia, Finland
UCB Pharma

Completed

Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease (Welcome2)

Crohn's Disease

United States, France, Italy, United Kingdom, Belgium, Germany, Spain, Switzerland, Canada, Netherlands, Austria, Sweden
GlaxoSmithKline

Completed

Effect of GSK1399686 in Patients With Mild to Moderately Active Ulcerative Colitis

Colitis, Ulcerative

Sweden, Germany, Belgium, Canada, Norway
Janssen Research & Development, LLC

Suspended

A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis

Crohn Disease | Ulcerative Colitis

Germany, United States, United Kingdom, Belgium
Novartis Pharmaceuticals

Completed

Efficacy, Safety and Tolerability of AEB071 in Patients With Active, Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

Germany, United States, Denmark, Poland
AbbVie

Active, not recruiting

Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD) (SEQUENCE)

Crohn's Disease (CD)

United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Korea, Republic of, Mexico, Netherlands, Poland, Romania, Russian Federation, Slo... and more
GlaxoSmithKline

Completed

GSK2982772 Study in Subjects With Ulcerative Colitis

Colitis, Ulcerative

Netherlands, United States, Germany, Russian Federation, Sweden, Poland, United Kingdom
AbbVie

Completed

Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease

Crohn's Disease

United States, Austria, Belgium, Canada, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Netherlands, Poland, Puerto Rico, Romania, Slovakia, Spain, Switzerland, Ukraine, United Kingdom
InDex Pharmaceuticals

Completed

The Efficacy and Safety of Cobitolimod (Kappaproct®) in Chronic Active Treatment Refractory Ulcerative Colitis Patients (COLLECT)

Colitis, Ulcerative

Czechia, France, Germany, Hungary, Italy, Poland, United Kingdom
Ferring Pharmaceuticals

Completed

A Trial Comparing the PICOPREP Tailored Dosing Schedule to the PICOPREP Day-before Dosing Schedule for Colon Cleansing in Preparation for Colonoscopy (OPTIMA)

Bowel Cleansing

France, Germany, Netherlands
Centocor, Inc.

Completed

A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy

Crohn's Disease

United States, France, United Kingdom, Germany, Spain, Belgium, Israel, Australia, Canada, Netherlands, New Zealand, Austria
GlaxoSmithKline

Terminated

Open-Label Extension Study of GSK1605786A (SHIELD-3)

Crohn's Disease

United States, France, Spain, Bulgaria, Poland, Ukraine, South Africa, Sweden, Israel, Korea, Republic of, Belgium, Australia, Austria, Canada, Chile, Czechia, Denmark, Estonia, Germany, Hong Kong, Hungary, Italy, Japan, New Zealand, Po... and more
GlaxoSmithKline

Completed

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease (SHIELD-1)

Crohn's Disease

United States, France, Netherlands, Spain, Germany, Poland, Belgium, South Africa, Sweden, Israel, Korea, Republic of, Australia, Austria, Canada, Czechia, Denmark, Hungary, Italy, Japan, New Zealand, Norway, Slovakia, United Kingdom
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002)

Ulcerative Colitis

United States, Georgia, Germany, Hungary, Moldova, Republic of, Poland, Ukraine, United Kingdom
Pfizer

Active, not recruiting

A Study to Learn About the Safety, Effects and Pharmacokinetics of Study Medication (PF-07054894) for the Treatment of Ulcerative Colitis

Ulcerative Colitis

United States, Poland, Germany
GlaxoSmithKline

Terminated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease (SHIELD-2)

Crohn's Disease

United States, France, Netherlands, Spain, Bulgaria, Poland, Ukraine, South Africa, Sweden, Israel, Korea, Republic of, Belgium, Australia, Austria, Canada, Chile, Czechia, Denmark, Estonia, Germany, Hong Kong, Hungary, Italy, Japan, New... and more
Janssen Research & Development, LLC

Completed

A Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human Anti-TNFα Antibody, in Pediatric Patients With Moderate to Severe Active Ulcerative Colitis

Colitis, Ulcerative

United States, France, Belgium, Israel, Canada, Netherlands, Austria, Poland, Denmark, Germany
Bristol-Myers Squibb

Terminated

A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative Colitis

Colitis, Ulcerative

United States, Australia, Canada, Germany, Poland, Puerto Rico, United Kingdom, Netherlands
Janssen-Cilag Ltd.

Recruiting

A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease (FUZION CD)

Fistulizing Crohns Disease | Perianal Crohns Disease

Netherlands, United States, Belgium, Korea, Republic of, Taiwan, Israel, Japan, Canada, Hungary, Germany, Greece, United Kingdom, Australia, Spain, Saudi Arabia, Poland, Turkey, Portugal, Czechia, Italy, Jordan, France
Galapagos NV

Completed

Efficacy and Safety of GLPG1205 in Subjects With Active Ulcerative Colitis (ORIGIN)

Ulcerative Colitis

Belgium, Czech Republic, Germany, Hungary, Poland, Russian Federation
Takeda
Takeda Development Center Americas, Inc.

Terminated

A Study of TAK-018 in Preventing the Recurrence of Crohn's Disease After Surgery

Crohn Disease

United States, Germany, Austria, France, United Kingdom
Klinikum Ludwigshafen

Completed

Influence of of a Lipid Emulsion on Inflammatory Response and Hepatic Function

Inflammatory Response | Hepatic Function

Germany
University of Cologne

Completed

Systemic Inflammatory Response Syndrome (SIRS) in Patients Undergoing Major Procedures in Oral and Maxillofacial Surgery

Systemic Inflammatory Response Syndrome (SIRS)

Germany
AstraZeneca
MedImmune Ltd

Completed

Evaluation of Efficacy and Safety of Tralokinumab in Patients With Active, Moderate-to-severe Ulcerative Colitis

Ulcerative Colitis

Italy, Poland, United Kingdom, France, Czech Republic, Germany
Ludwig-Maximilians - University of Munich

Completed

The Effect of Neu-P11 on Symptoms in Patients With D-IBS (Neu-P11)

Diarrhea- Irritable Bowel Syndrome

Germany
University of Ulm

Completed

Biopotentials for Clinician Satisfaction With Sedation in Colonoscopy (BCSSC)

Bowel Disease

Germany
Boehringer Ingelheim

Completed

BI 655130 Long-term Treatment in Patients With moderate-to Severe Ulcerative Colitis

Colitis, Ulcerative

Spain, United Kingdom, United States, Belgium, Germany, Italy, Austria, Canada, Japan, Korea, Republic of, Russian Federation, Poland
Olympus Europe SE & Co. KG

Completed

A Clinical Study With the Medical Device PowerSpiral for Deep Enteroscopy (SAMISEN)

Small Bowel Disease

Finland, Germany, Belgium, Denmark, France, Norway
University of Ulm
Charite University, Berlin, Germany; Klinikum Ludwigsburg; Helios Klinikum Krefeld and other collaborators

Unknown

Allogeneic Microbiota-reconstitution (AMR) in Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) (AMIRA)

Diarrhea-predominant Irritable Bowel Syndrome

Germany
Amgen

Recruiting

Long-term Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

United States, Germany, Japan, Denmark, Romania, Argentina, Bulgaria, Hungary, Korea, Republic of, Mexico, Poland, Switzerland, Turkey
Genentech, Inc.

Completed

A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of rhuMAb Beta7 in Patients With Ulcerative Colitis

Ulcerative Colitis

Belgium, United States, Canada, Germany, Netherlands, United Kingdom
Shire

Completed

Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Volunteers With Crohn's Disease Or Ulcerative Colitis Who Failed Or Did Not Tolerate Anti-TNFs (TOSCA)

Crohn's Disease | Ulcerative Colitis | Ileitis | Granulomatous Colitis | Ileo-colonic and Colonic Crohn's Disease | Regional Enteritis

France, Belgium, Austria, Germany, Netherlands
Celgene

Active, not recruiting

An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

United States, Germany, Greece, United Kingdom, Hungary, Belgium, Slovakia, Bulgaria, Italy, Australia, Israel, Belarus, Romania, Ukraine
Pfizer
Athersys, Inc

Completed

A Study To Investigate The Safety And Possible Clinical Benefit Of Multistem(r) In Patients With Moderate To Severe Ulcerative Colitis

Colitis, Ulcerative

United States, Canada, Germany, Italy, Hungary, Belgium, Slovakia, Sweden
Pfizer

Terminated

Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission.

Ulcerative Colitis

United States, Australia, Italy, Korea, Republic of, Belgium, Israel, Turkey, Saudi Arabia, Germany, Serbia
Janssen Research & Development, LLC

Active, not recruiting

A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC) (UNIFI Jr)

Colitis, Ulcerative

United States, Israel, Belgium, Hungary, Japan, Germany, Poland, United Kingdom, Russian Federation
Medtronic - MITG

Completed

Evaluation of PillCam™ Colon 2 in Visualization of the Colon

Colonic Diseases | and Large Bowel Diseases

Spain, Sweden, Germany, Belgium, France, Italy, Netherlands
Boehringer Ingelheim

Completed

BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis

Colitis, Ulcerative

Canada, United States, Spain, United Kingdom, Belgium, Germany, Italy, Japan, Korea, Republic of, Poland, Russian Federation, Austria
sigma-tau i.f.r. S.p.A.
PRA Health Sciences

Terminated

Propionyl-L-Carnitine Hydrochloride in Patients With Mild Ulcerative Colitis; Efficacy, Safety and Tolerability Study

Ulcerative Colitis

Poland, Hungary, Austria, France, Germany, Latvia, Lithuania, Spain

Clinical Trials on Inflammatory Bowel Diseases in Germany

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Thailand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations